OBJECTIVES: Phenothiazines have been shown to exhibit in vitro and in vivo activity against Mycobacterium tuberculosis (Mtb) and multidrug-resistant Mtb. They are predicted to target the genetically validated respiratory chain component type II NADH:quinone oxidoreductase (Ndh). Using a set of compounds containing the phenothiazine pharmacophore, we have (i) investigated whether chemical validation data support the molecular target and (ii) evaluated pharmacophore tractability for further drug development. METHODS: Recombinant Mtb Ndh was generated and its functionality confirmed by steady-state kinetics. Pharmacodynamic profiling of the phenothiazines, including antitubercular efficacy in aerobic and O2-limited conditions, time-kill assays and isobole analyses against first-line antituberculars, was performed. Potential mitochondrial toxicity was assessed in a modified HepG2 cell-line assay and against bovine cytochrome bc1. RESULTS: Steady-state kinetic analyses revealed a substrate preference for coenzyme Q2 and an inability to utilize NADPH. A positive correlation between recombinant Ndh inhibition and kill of aerobically cultured Mtb was observed, whilst enhanced potency was demonstrated in a hypoxic model. Time-kill studies revealed the phenothiazines to be bactericidal whilst isobolograms exposed antagonism with isoniazid, indicative of intracellular NADH/NAD(+) couple perturbation. At therapeutic levels, phenothiazine-mediated toxicity was appreciable; however, specific mitochondrial targeting was excluded. CONCLUSIONS: Data generated support the hypothesis that Ndh is the molecular target of phenothiazines. The favourable pharmacodynamic properties of the phenothiazines are consistent with a target product profile that includes activity against dormant/persistent bacilli, rapid bactericidal activity and activity against drug-resistant Mtb by a previously unexploited mode of action. These properties warrant further medicinal chemistry to improve potency and safety.
OBJECTIVES: Phenothiazines have been shown to exhibit in vitro and in vivo activity against Mycobacterium tuberculosis (Mtb) and multidrug-resistant Mtb. They are predicted to target the genetically validated respiratory chain component type II NADH:quinone oxidoreductase (Ndh). Using a set of compounds containing the phenothiazine pharmacophore, we have (i) investigated whether chemical validation data support the molecular target and (ii) evaluated pharmacophore tractability for further drug development. METHODS: Recombinant Mtb Ndh was generated and its functionality confirmed by steady-state kinetics. Pharmacodynamic profiling of the phenothiazines, including antitubercular efficacy in aerobic and O2-limited conditions, time-kill assays and isobole analyses against first-line antituberculars, was performed. Potential mitochondrial toxicity was assessed in a modified HepG2 cell-line assay and against bovine cytochrome bc1. RESULTS: Steady-state kinetic analyses revealed a substrate preference for coenzyme Q2 and an inability to utilize NADPH. A positive correlation between recombinant Ndh inhibition and kill of aerobically cultured Mtb was observed, whilst enhanced potency was demonstrated in a hypoxic model. Time-kill studies revealed the phenothiazines to be bactericidal whilst isobolograms exposed antagonism with isoniazid, indicative of intracellular NADH/NAD(+) couple perturbation. At therapeutic levels, phenothiazine-mediated toxicity was appreciable; however, specific mitochondrial targeting was excluded. CONCLUSIONS: Data generated support the hypothesis that Ndh is the molecular target of phenothiazines. The favourable pharmacodynamic properties of the phenothiazines are consistent with a target product profile that includes activity against dormant/persistent bacilli, rapid bactericidal activity and activity against drug-resistant Mtb by a previously unexploited mode of action. These properties warrant further medicinal chemistry to improve potency and safety.
Authors: Victoria Barton; Nicholas Fisher; Giancarlo A Biagini; Stephen A Ward; Paul M O'Neill Journal: Curr Opin Chem Biol Date: 2010-08 Impact factor: 8.822
Authors: Aaron B Bate; Jay H Kalin; Eric M Fooksman; Erica L Amorose; Cristofer M Price; Heather M Williams; Michael J Rodig; Miguel O Mitchell; Sang Hyun Cho; Yuehong Wang; Scott G Franzblau Journal: Bioorg Med Chem Lett Date: 2006-12-02 Impact factor: 2.823
Authors: Gregory M Cook; Kiel Hards; Elyse Dunn; Adam Heikal; Yoshio Nakatani; Chris Greening; Dean C Crick; Fabio L Fontes; Kevin Pethe; Erik Hasenoehrl; Michael Berney Journal: Microbiol Spectr Date: 2017-06
Authors: Michael B Harbut; Baiyuan Yang; Renhe Liu; Takahiro Yano; Catherine Vilchèze; Bo Cheng; Jonathan Lockner; Hui Guo; Chenguang Yu; Scott G Franzblau; H Mike Petrassi; William R Jacobs; Harvey Rubin; Arnab K Chatterjee; Feng Wang Journal: Angew Chem Int Ed Engl Date: 2018-02-22 Impact factor: 15.336
Authors: Michael J Capper; Paul M O'Neill; Nicholas Fisher; Richard W Strange; Darren Moss; Stephen A Ward; Neil G Berry; Alexandre S Lawrenson; S Samar Hasnain; Giancarlo A Biagini; Svetlana V Antonyuk Journal: Proc Natl Acad Sci U S A Date: 2015-01-06 Impact factor: 11.205
Authors: Diana Machado; David Pires; João Perdigão; Isabel Couto; Isabel Portugal; Marta Martins; Leonard Amaral; Elsa Anes; Miguel Viveiros Journal: PLoS One Date: 2016-02-26 Impact factor: 3.240